{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T17:34:10Z","timestamp":1772818450941,"version":"3.50.1"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T00:00:00Z","timestamp":1685664000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>SARS-CoV-2, the virus behind the COVID-19 pandemic, has changed over time to the extent that the current virus is substantially different from what originally led to the pandemic in 2019\u20132020. Viral variants have modified the severity and transmissibility of the disease and continue do so. How much of this change is due to viral fitness versus a response to immune pressure is hard to define. One class of antibodies that continues to afford some level of protection from emerging variants are those that closely overlap the binding site for angiotensin-converting enzyme 2 (ACE2) on the receptor binding domain (RBD). Some members of this class that were identified early in the course of the pandemic arose from the V<jats:sub>H<\/jats:sub> 3-53 germline gene (IGHV3-53*01) and had short heavy chain complementarity-determining region 3s (CDR H3s). Here, we describe the molecular basis of the SARS-CoV-2 RBD recognition by the anti-RBD monoclonal antibody CoV11 isolated early in the COVID-19 pandemic and show how its unique mode of binding the RBD determines its neutralization breadth. CoV11 utilizes a heavy chain V<jats:sub>H<\/jats:sub> 3-53 and a light chain V<jats:sub>K<\/jats:sub> 3-20 germline sequence to bind to the RBD. Two of CoV11\u2019s four heavy chain changes from the V<jats:sub>H<\/jats:sub> 3-53 germline sequence, <jats:inline-formula><mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" display=\"inline\" id=\"im1\"><mml:mrow><mml:mi>T<\/mml:mi><mml:mi>h<\/mml:mi><mml:msubsup><mml:mi>r<\/mml:mi><mml:mrow><mml:mi>F<\/mml:mi><mml:mi>W<\/mml:mi><mml:mi>R<\/mml:mi><mml:mtext>\u2009<\/mml:mtext><mml:mi>H<\/mml:mi><mml:mn>1<\/mml:mn><\/mml:mrow><mml:mrow><mml:mn>28<\/mml:mn><\/mml:mrow><\/mml:msubsup><\/mml:mrow><\/mml:math><\/jats:inline-formula> to Ile and <jats:inline-formula><mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" display=\"inline\" id=\"im2\"><mml:mrow><mml:mi>S<\/mml:mi><mml:mi>e<\/mml:mi><mml:msubsup><mml:mi>r<\/mml:mi><mml:mrow><mml:mi>C<\/mml:mi><mml:mi>D<\/mml:mi><mml:mi>R<\/mml:mi><mml:mtext>\u2009<\/mml:mtext><mml:mi>H<\/mml:mi><mml:mn>1<\/mml:mn><\/mml:mrow><mml:mrow><mml:mn>31<\/mml:mn><\/mml:mrow><\/mml:msubsup><\/mml:mrow><\/mml:math><\/jats:inline-formula> to Arg, and some unique features in its CDR H3 increase its affinity to the RBD, while the four light chain changes from the V<jats:sub>K<\/jats:sub> 3-20 germline sequence sit outside of the RBD binding site. Antibodies of this type can retain significant affinity and neutralization potency against variants of concern (VOCs) that have diverged significantly from original virus lineage such as the prevalent omicron variant. We also discuss the mechanism by which V<jats:sub>H<\/jats:sub> 3-53 encoded antibodies recognize spike antigen and show how minimal changes to their sequence, their choice of light chain, and their mode of binding influence their affinity and impact their neutralization breadth.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1178355","type":"journal-article","created":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T12:42:15Z","timestamp":1685709735000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["The molecular basis of the neutralization breadth of the RBD-specific antibody CoV11"],"prefix":"10.3389","volume":"14","author":[{"given":"William D.","family":"Tolbert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaozong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lulu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehdi","family":"Benlarbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shilei","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohini","family":"Manickam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Pangaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dung N.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suneetha","family":"Gottumukkala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marceline","family":"C\u00f4t\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank J.","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9s","family":"Finzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra R.","family":"Tehrani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad M.","family":"Sajadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marzena","family":"Pazgier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-020-00459-7","article-title":"Characteristics of SARS-CoV-2 and COVID-19","volume":"19","author":"Hu","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-021-03619-8","article-title":"Beyond omicron: what's next for COVID's viral evolution","volume":"600","author":"Callaway","year":"2021","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"B4","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2003138117","article-title":"Cell entry mechanisms of SARS-CoV-2","volume":"117","author":"Shang","year":"2020","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2180-5","article-title":"Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor","volume":"581","author":"Lan","year":"2020","journal-title":"Nature"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-021-00487-9","article-title":"Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies","volume":"31","author":"Yan","year":"2021","journal-title":"Cell Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2179-y","article-title":"Structural basis of receptor recognition by SARS-CoV-2","volume":"581","author":"Shang","year":"2020","journal-title":"Nature"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2022586118","article-title":"The effect of the D614G substitution on the structure of the spike glycoprotein of SARS-CoV-2","volume":"118","author":"Benton","year":"2021","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B10","doi-asserted-by":"publisher","first-page":"6013","DOI":"10.1038\/s41467-020-19808-4","article-title":"SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity","volume":"11","author":"Zhang","year":"2020","journal-title":"Nat Commun"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd2321","article-title":"Structural basis of a shared antibody response to SARS-CoV-2","volume":"369","author":"Yuan","year":"2020","journal-title":"Science"},{"key":"B12","doi-asserted-by":"publisher","first-page":"108274","DOI":"10.1016\/j.celrep.2020.108274","article-title":"An alternative binding mode of IGHV3-53 antibodies to the SARS-CoV-2 receptor binding domain","volume":"33","author":"Wu","year":"2020","journal-title":"Cell Rep"},{"key":"B13","doi-asserted-by":"publisher","first-page":"5413","DOI":"10.1038\/s41467-020-19231-9","article-title":"Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation","volume":"11","author":"Hurlburt","year":"2020","journal-title":"Nat Commun"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2852-1","article-title":"SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies","volume":"588","author":"Barnes","year":"2020","journal-title":"Nature"},{"key":"B15","doi-asserted-by":"publisher","first-page":"4210","DOI":"10.1038\/s41467-021-24514-w","article-title":"Potent and protective IGHV3-53\/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat Commun"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/j.immuni.2021.07.008","article-title":"Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations","volume":"54","author":"Muecksch","year":"2021","journal-title":"Immunity"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1016\/j.cell.2021.02.033","article-title":"Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera","volume":"184","author":"Supasa","year":"2021","journal-title":"Cell"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1016\/j.cell.2021.04.032","article-title":"B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV","volume":"184","author":"Scheid","year":"2021","journal-title":"Cell"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1016\/j.cell.2021.03.055","article-title":"Antibody evasion by the P.1 strain of SARS-CoV-2","volume":"184","author":"Dejnirattisai","year":"2021","journal-title":"Cell"},{"key":"B20","doi-asserted-by":"publisher","first-page":"110210","DOI":"10.1016\/j.celrep.2021.110210","article-title":"Structural basis and mode of action for two broadly neutralizing antibodies against SARS-CoV-2 emerging variants of concern","volume":"38","author":"Li","year":"2022","journal-title":"Cell Rep"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2021.1925594","article-title":"Germline IGHV3-53-encoded RBD-targeting neutralizing antibodies are commonly present in the antibody repertoires of COVID-19 patients","volume":"10","author":"Yan","year":"2021","journal-title":"Emerg Microbes Infect"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1126\/science.abh2315","article-title":"Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: a global consortium study","volume":"374","author":"Hastie","year":"2021","journal-title":"Science"},{"key":"B23","doi-asserted-by":"publisher","first-page":"111998","DOI":"10.1016\/j.celrep.2023.111998","article-title":"Spike recognition and neutralization of SARS-CoV-2 omicron subvariants elicited after the third dose of mRNA vaccine","volume":"42","author":"Tauzin","year":"2023","journal-title":"Cell Rep"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11020242","article-title":"Humoral responses against BQ.1.1 elicited after breakthrough infection and SARS-CoV-2 mRNA vaccination","volume":"11","author":"Tauzin","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1101\/2022.12.15.520606","article-title":"Identification of broad, potent antibodies to functionally constrained regions of SARS-CoV-2 spike following a breakthrough infection","volume":"29","author":"Guenthoer","year":"2023","journal-title":"bioRxiv"},{"key":"B26","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/mps1010008","article-title":"Pseudotype neutralization assays: from laboratory bench to data analysis","volume":"1","author":"Ferrara","year":"2018","journal-title":"Methods Protoc"},{"key":"B27","doi-asserted-by":"publisher","first-page":"105783","DOI":"10.1016\/j.isci.2022.105783","article-title":"Molecular basis for antiviral activity of two pediatric neutralizing antibodies targeting SARS-CoV-2 spike RBD","volume":"26","author":"Chen","year":"2023","journal-title":"iScience"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S0076-6879(97)76066-X","article-title":"Processing of X-ray diffraction data collected in oscillation mode","volume":"276","author":"Otwinowski","year":"1997","journal-title":"Meth Enzymol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1107\/S0907444994003112","article-title":"The CCP4 suite: programs for protein crystallography","volume":"50","year":"1994","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1107\/S0907444909052925","article-title":"PHENIX: a comprehensive Python-based system for macromolecular structure solution","volume":"66","author":"Adams","year":"2010","journal-title":"Acta Crystallogr D Biol Crystallogr D66"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1107\/S0021889800018227","article-title":"Global indicators of X-ray data quality","volume":"34","author":"Weiss","year":"2001","journal-title":"J Appl Cryst"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1126\/science.1218231","article-title":"Linking crystallographic model and data quality","volume":"336","author":"Karplus","year":"2012","journal-title":"Science"},{"key":"B33","volume-title":"Free r value: cross-validation in crystallography, methods in enzymology","author":"Brunger","year":"1997"},{"key":"B34","article-title":"Structure of antibody combining sites","volume":"127","author":"Kabat","year":"1976","journal-title":"Ann Immunol (Paris)"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.23750\/abm.v93i1.12210","article-title":"Delta variant: the new challenge of COVID-19 pandemic, an overview of epidemiological, clinical, and immune characteristics","volume":"93","author":"Samieefar","year":"2022","journal-title":"Acta BioMed"},{"key":"B36","doi-asserted-by":"publisher","first-page":"100929","DOI":"10.1016\/j.nmni.2021.100929","article-title":"Genetic emergence of B.1.617.2 in COVID-19","volume":"43","author":"Kirola","year":"2021","journal-title":"New Microbes New Infect"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04245-0","article-title":"The N501Y spike substitution enhances SARS-CoV-2 infection and transmission","volume":"602","author":"Liu","year":"2022","journal-title":"Nature"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc5902","article-title":"Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability","volume":"369","author":"Brouwer","year":"2020","journal-title":"Science"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc7520","article-title":"Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model","volume":"369","author":"Rogers","year":"2020","journal-title":"Science"},{"key":"B40","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.cell.2020.05.025","article-title":"Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' b cells","volume":"182","author":"Cao","year":"2020","journal-title":"Cell"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1178355\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T12:42:19Z","timestamp":1685709739000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1178355\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,2]]},"references-count":40,"alternative-id":["10.3389\/fimmu.2023.1178355"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1178355","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,2]]},"article-number":"1178355"}}